Clinical Trial of Integrated Treatment for Pain and Opioid Dependence (POD)
Primary Purpose
Opiate Dependence, Chronic Pain
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CBT
Buprenorphine
Educational Counseling
Physician Management
Sponsored by
About this trial
This is an interventional treatment trial for Opiate Dependence
Eligibility Criteria
Inclusion Criteria:
- 18 years of age or older
- prescription opioid addiction criteria
- moderate to severe chronic pain
- seeking or interested in buprenorphine maintenance
- understand English
Exclusion Criteria:
- methadone maintenance at a dose greater than 40 mg daily
- current suicide or homicide risk
- life-threatening or unstable medical problem
- pregnancy
Sites / Locations
- Methadone Research Unit
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
CBT for POD
Educational Counseling for POD
Physician Management
Arm Description
Integrated cognitive behavioral therapy for chronic pain and opioid dependence
Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
Outcomes
Primary Outcome Measures
Pain Intensity
Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe.
Number of Opioid-negative Urine Toxicology Tests
Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled "Reduced illicit opioid use" and the timeframe was listed as 16 weeks.
Pain Interference
Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference.
Secondary Outcome Measures
Full Information
NCT ID
NCT00634803
First Posted
January 2, 2008
Last Updated
July 29, 2021
Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT00634803
Brief Title
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Acronym
POD
Official Title
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to develop an effective psychotherapy for chronic pain and opioid dependence.
Detailed Description
This study aims to develop a novel manualized intervention using tailored cognitive-behavioral treatment (CBT) and buprenorphine medication to effectively treat the co-occurring disorders of non-malignant pain and opioid dependence (POD).
Specific Aims:
To conduct a pre-pilot phase with 16 patients with POD receiving buprenorphine maintenance treatment (BMT). In the pre-pilot phase, we will also explore the effects of different daily buprenorphine dosages on pain and opiate use.
To conduct a pilot randomized, clinical trial to obtain data regarding the feasibility, acceptability and efficacy (compared to Physician Management(PM) only) of manual-guided CBT or Educational Counseling (EC) for patients with POD treated with BMT (N=75).
The secondary outcomes: Development of a Treatment Manual and Development and Modification of Initial Therapy Training and Process Rating Measures were process measures and not been to be included as measures associated with RCT. These outcomes were removed when the RCT results were entered. In addition, outcomes were renamed for clarification.
At results entry, the timeframe (16 weeks) was also corrected to account for the actual timeframe used for analysis in the study. The 16-week study period listed in the protocol included a 2-week buprenorphine induction period (before randomization) and up to a 2-week post-conclusion of the clinical trial continuation on buprenorphine and referral to continuing treatment. In prior studies with buprenorphine, the study team had observed an artificially high attrition during the last 2 weeks of the planned study protocol, when participants were attempting to transition to available clinical treatments outside of the study. Consequently, as per the original study protocol for this study, the plan was to analyze intake and induction data (as baseline data) and then the data from the first 12-weeks post-randomization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opiate Dependence, Chronic Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CBT for POD
Arm Type
Experimental
Arm Description
Integrated cognitive behavioral therapy for chronic pain and opioid dependence
Arm Title
Educational Counseling for POD
Arm Type
Active Comparator
Arm Description
Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
Arm Title
Physician Management
Arm Type
Active Comparator
Arm Description
PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
Intervention Type
Behavioral
Intervention Name(s)
CBT
Intervention Description
Cognitive behavioral therapy
Intervention Type
Drug
Intervention Name(s)
Buprenorphine
Intervention Description
buprenorphine/naloxone
Intervention Type
Other
Intervention Name(s)
Educational Counseling
Intervention Description
Didactic, lecture-discussion format to supplement information and advice provided by physicians
Intervention Type
Other
Intervention Name(s)
Physician Management
Intervention Description
Brief physician counseling
Primary Outcome Measure Information:
Title
Pain Intensity
Description
Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe.
Time Frame
3 months
Title
Number of Opioid-negative Urine Toxicology Tests
Description
Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled "Reduced illicit opioid use" and the timeframe was listed as 16 weeks.
Time Frame
3 Months
Title
Pain Interference
Description
Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference.
Time Frame
3 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age or older
prescription opioid addiction criteria
moderate to severe chronic pain
seeking or interested in buprenorphine maintenance
understand English
Exclusion Criteria:
methadone maintenance at a dose greater than 40 mg daily
current suicide or homicide risk
life-threatening or unstable medical problem
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard S Schottenfeld, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Methadone Research Unit
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
27574837
Citation
Barry DT, Cutter CJ, Beitel M, Kerns RD, Liong C, Schottenfeld RS. Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder. J Clin Psychiatry. 2016 Oct;77(10):1413-1419. doi: 10.4088/JCP.15m09963.
Results Reference
derived
Learn more about this trial
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
We'll reach out to this number within 24 hrs